重组人血管内皮抑制素窗口期联合化疗治疗晚期结直肠癌的临床疗效分析

Clinical Effect Analysis of Recombinant Human Hemoendothelial Inhibin Combined with Chemotherapy at Window Period in the Treatment of Late Colorectal Cancer

目的:探究采取重组人血管内皮抑制素窗口期联合化疗治疗晚期结直肠癌的作用和临床效果。方法:将本院70例晚期结直肠癌患者随机分为观察组和对照组,每组各35例。观察组患者采取重组人血管内皮抑制素窗口期联合化疗治疗,对照组采取常规化疗。比较2组疗效,毒副反应及生活质量等情况。结果:观察组客观治疗有效率和疾病控制率均高于对照组(P <0.05);2组患者毒副反应严重程度均在Ⅰ级~Ⅱ级,差异无统计学意义(P>0.05);观察组治疗后生活质量评分低于对照组(P <0.05),机体功能状态评分高于对照组(P <0.05)。结论:重组人血管内皮抑制素窗口期联合化疗治疗晚期结直肠癌有助于快速稳定病情,降低对其他器官组织的损伤,患者机体耐受性较好,可以在治疗中发挥出巨大作用,临床应用价值较高。

Objective To investigate the clinical effect of recombinant human hemoendothelial inhibin(RHHEI) combined with chemotherapy at window period for late colorectal cancer.Methods Randomly 70 patients with late colorectal cancer treated in author’s hospital into observation group(35 cases,adopted RHHEI combined with chemotherapy at window period) and control group(35 cases,routine chemotherapy);then,compared effect,patients’ unward reaction and quality of life between the two groups.Results In effective rate and the controlled rate of disease,in patients’ quality of life,as well as in body’s function ratings after treatment observation group was respectively higher,lower,as well as higher than control group(all,P <0.05);but,in the severity of unward reaction there was no statistical difference between the two groups(all,at Ⅰ-Ⅱ grade,P>0.05).Conclusion RHHEI combined with chemotheroapy at window period for treating late colorectal cancer is helpful to fastly stablize condition,reduce other organs and tissues injuried,so that patients’ body tolerance better,thus plays significant role in the treatment,also,has higer clinical application value.